Does the use of corticosteroid nasal spray play a role in the development of central serous chorioretinopathy?

Aim: In this study, we aimed to investigate effects of corticosteroid-containing nasal spray use on central serous chorioretinopathy (CSC) development and thickness of choroid and retinal pigment epithelium–Bruch membrane complex (RPE-BM). Materials and Methods: Twenty-nine patients (18 female, 11 male) receiving nasal mometasone spray treatment were included in the study. Systolic blood pressure (SBP), diastolic blood pressure (DBP), visual acuity, intraocular pressure and choroidal and RPE-BM thickness were measured before and one week and one month after the medication. Optical coherence tomography sections were examined for CSC development. The measurements were made from the right eye. Results: Central serous chorioretinopathy was not detected in any of the patients. Mean choroidal thickness values did not show any statistically significant changes between the initial and follow-up measurements: On the temporal side 292.48±73.02 μm in beginning, 296.83±79.09 μm one week after, 295.41±74.13 μm one month after (p=0.405); under the fovea 360.62±92.44 μm in beginning, 364.04±93.65 μm one week after, 365.66±95.86 μm one month after (p=0.208); on the nasal side 282.86±96.11 μm in beginning, 285.28±93.25 μm one week after, 284.28±98.14 μm one month after (p=0.819); and RPE-BM 21.65±2.86 μm in beginning, 21.24±2.61 μm one week after, 21.58±2.09 μm one month after. Differences were not statistically significant (p=0.450). There was no significant difference in intraocular pressure (p=0.450), SBP (p=0.257) and DBP (p=0.249) measurements. Discussion and Conclusion: Further studies are needed to determine the incidence of corticosteroid-induced CSC and the cause–effect relationship between CSC development and choroid or RPE-BM thickness.